XML 67 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2021
Disaggregation of Revenue [Abstract]  
Disaggregation of Revenue [Table Text Block] The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
Year Ended December 31,
202120202019
BusinessesU.S.OUSTotalU.S.OUSTotalU.S.OUSTotal
Endoscopy$1,222 $919 $2,141 $1,000 $780 $1,780 $1,080 $814 $1,894 
Urology and Pelvic Health1,120 463 1,583 918 368 1,286 1,005 408 1,413 
Cardiac Rhythm Management1,214 805 2,019 992 712 1,704 1,135 804 1,939 
Electrophysiology128 237 365 118 169 287 148 180 329 
Neuromodulation713 196 909 610 151 761 695 178 873 
Interventional Cardiology1,508 1,530 3,038 981 1,317 2,299 1,293 1,522 2,816 
Peripheral Interventions996 824 1,820 888 689 1,577 741 651 1,392 
Specialty Pharmaceuticals10 4 13 193 27 219 70 11 81 
Net Sales$6,911 $4,978 $11,888 $5,701 $4,212 $9,913 $6,167 $4,569 $10,735 

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales and income (loss) before income taxes include Specialty Pharmaceuticals up to the date of the closing of the transaction.

Year Ended December 31,
Geographic Regions202120202019
U.S.$6,901 $5,508 $6,097 
EMEA (Europe, Middle East and Africa)2,518 2,097 2,264 
APAC (Asia-Pacific)2,070 1,781 1,898 
LACA (Latin America and Canada)386 307 395 
Medical Devices11,875 9,694 10,654 
U.S.10 193 70 
International4 27 11 
Specialty Pharmaceuticals13 219 81 
Net Sales$11,888 $9,913 $10,735 
Emerging Markets(1)
$1,429 $1,138 $1,282 
(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior period amounts to conform to the current year's presentation.